Glaukos Corp (GKOS) reported quarterly earnings results on Tuesday, May-3-2016. The company said it had a profit of $0.03 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.18. Analysts had a consensus of $-0.15. The company posted revenue of $23.10 million in the period, compared to analysts expectations of $18.82 million. The company’s revenue was up 57.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.40 EPS.
Many Wall Street Analysts have commented on Glaukos Corp. Glaukos Corp was Initiated by Stifel to “Hold” on Apr 8, 2016. Piper Jaffray Initiated Glaukos Corp on Feb 9, 2016 to “Overweight”, Price Target of the shares are set at $19.
Glaukos Corp opened for trading at $19.37 and hit $19.99 on the upside on Monday, eventually ending the session at $19.78, with a gain of 4.99% or 0.94 points. The heightened volatility saw the trading volume jump to 5,46,734 shares. Company has a market cap of $640 M.
In a different news, on Jan 4, 2016, Richard L Harrison (CFO) purchased 1,388 shares at $15.30 per share price. According to the SEC, on Jan 4, 2016, Thomas William Burns (CEO) purchased 1,388 shares at $15.30 per share price. On Jun 30, 2015, Robert J More (director) purchased 5,000 shares at $18.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company is engaged in the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent an MIGS device measuring one millimeter long and 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye’s anterior chamber through a small corneal incision. Glaukos is also engaged in developing a portfolio of micro-scale injectable therapies including three pipeline products namely the iStent Inject the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.